Fig. 5.

RosA restores the expression of Type II collagen, Aggrecan and Sox9 reduced by OA progression.

(A, B, C, D) Chondrocytes were co-treated with IL-β and RosA for 24 h Sox9, Col2a1, and Acan expressions were evaluated by RT-PCR (A) and densitometry (B; Sox9, C; Col2a1, and D; Acan) analysis. (E) Sox9, Type II collagen and Aggrecan expressions in cartilage explant after being co-treated with IL-1β and RosA measured by Immunohistochemical staining and (F) quantification (Sox9; upper panel, Type II collagen; middle panel, Aggrecan; lower panel). Values are presented as the mean ± standard deviation. One-way analysis of variance followed by Bonferroni's test was used to determine significant differences. None significant (N.S), ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and #P < 0.05 compared to the control group. Original gel (Fig. S9) can be seen in supplementary figures file.